Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The Company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
์ข
๋ชฉ ์ฝ๋ HOTH
ํ์ฌ ์ด๋ฆHoth Therapeutics Inc
์์ฅ์ผFeb 15, 2019
CEOKnie (Robb)
์ง์ ์2
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃFeb 15
์ฃผ์1177 Avenue Of The Americas
๋์NEW YORK
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ10036
์ ํ16467562997
์น์ฌ์ดํธhttps://hoththerapeutics.com/
์ข
๋ชฉ ์ฝ๋ HOTH
์์ฅ์ผFeb 15, 2019
CEOKnie (Robb)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์